Phase 3 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with colon cancer (a specific type called adenocarcinoma) that has not yet been treated
• People whose colon cancer has been confirmed by a pathology test (laboratory analysis of tissue)
• People whose cancer is considered removable by surgery, based on how far it has spread locally (classified as T4N0 or Stage III)
• People whose cancer can be measured or assessed using medical imaging (such as a CT scan)
• People whose tumor has a specific biological marker — either something called "dMMR" or "MSI-H" — which relates to how the cancer's DNA repair system works (confirm with trial site)

Who may not be able to join:

• People whose cancer has spread to distant parts of the body (metastatic disease)
• People who have already received any treatment for their current colon cancer diagnosis, including chemotherapy, immunotherapy, targeted therapy, radiation therapy, or surgery
• People whose tumor is causing a serious blockage of the bowel that requires urgent surgery — however, people who previously had a bowel blockage that was relieved by a surgical opening in the abdomen (a stoma) may still be considered; people who had a blockage treated with a colon stent are not eligible
• People who have had a major surgery, open biopsy, or serious physical injury within the 28 days before joining the trial
• People who have a history of a lung condition involving inflammation or scarring (interstitial lung disease or pneumonitis), or inflammation of the bowel caused by radiation
• People who have cirrhosis or serious liver or bile duct disease, including conditions such as fluid build-up in the abdomen, confusion caused by liver problems, abnormal blood clotting, low protein levels, swollen veins in the food pipe or stomach, or ongoing yellowing of the skin
• People who have previously had a stem cell transplant from a donor or an organ transplant
• People who are currently receiving any other cancer treatment or experimental therapy
• People who are pregnant, breastfeeding, or planning to become pregnant during the period covered by the study
• People who have had a severe allergic or anaphylactic reaction to certain types of antibody-based medicines, or who are known to be allergic to the study drugs (dostarlimab, FOLFOX, or CAPEOX) or their ingredients

Important: Always verify eligibility with the trial site directly before applying.